Legacy mercury and stoichiometry with C, N, and S in soil, pore water, and stream water across the upland‐wetland interface: The influence of hydrogeologic setting

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/99104/1/2012JG002250R_Appendix_C_120728.pdfhttp://deepblue.lib.umich.edu/bitstream/2027.42/99104/2/jgrg20066.pdfhttp://deepblue.lib.umich.edu/bitstream/2027.42/99104/3/2012JG002250R_Appendix_B_100903.pdfhttp://deepblue.lib.umich.edu/bitstream/2027.42/99104/4/2012JG002250R_Appendix_A_100907.pd

Deposition of mercury in forests across a montane elevation gradient: Elevational and seasonal patterns in methylmercury inputs and production

Global mercury contamination largely results from direct primary atmospheric and secondary legacy emissions, which can be deposited to ecosystems, converted to methylmercury, and bioaccumulated along food chains. We examined organic horizon soil samples collected across an elevational gradient on Whiteface Mountain in the Adirondack region of New York State, USA to determine spatial patterns in methylmercury concentrations across a forested montane landscape. We found that soil methylmercury concentrations were highest in the midelevation coniferous zone (0.39 ± 0.07 ng/g) compared to the higher elevation alpine zone (0.28 ± 0.04 ng/g) and particularly the lower elevation deciduous zone (0.17 ± 0.02 ng/g), while the percent of total mercury as methylmercury in soils decreased with elevation. We also found a seasonal pattern in soil methylmercury concentrations, with peak methylmercury values occurring in July. Given elevational patterns in temperature and bioavailable total mercury (derived from mineralization of soil organic matter), soil methylmercury concentrations appear to be driven by soil processing of ionic Hg, as opposed to atmospheric deposition of methylmercury. These methylmercury results are consistent with spatial patterns of mercury concentrations in songbird species observed from other studies, suggesting that future declines in mercury emissions could be important for reducing exposure of mercury to montane avian species.Key PointsTotal mercury and methylmercury concentrations and fluxes are examined across an elevational gradient on an Adirondack, New York mountainMethylmercury concentrations across the elevational gradient are greatest in midelevation coniferous zonesSoil methylmercury concentrations are driven by the internal processing of mercury, rather than external inputs of methylmercuryPlain Language SummaryOnce mercury is emitted into the atmosphere by anthropogenic sources, it can be deposited onto the Earth’s surface. This mercury can then be converted to its toxic form of methylmercury by microbes in the soil and can accumulate in birds, altering physiology, behavior, and reproduction. We examined soils from Whiteface Mountain in the Adirondack region of New York State, USA to determine patterns in the production of methylmercury. We found that methylmercury in soils was highest in the mid‐elevation coniferous forests of the mountain and that the concentration appeared to be driven by soil microbes rather than direct deposition of mercury from the atmosphere. The finding of peak methylmercury at mid‐elevations was consistent with previous studies showing peak bird mercury concentrations at the same elevation. Thus, reductions in methylmercury concentrations in these forests is important to reducing bird mercury concentrations.Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/138300/1/jgrg20832_am.pdfhttps://deepblue.lib.umich.edu/bitstream/2027.42/138300/2/jgrg20832-sup-0001-2016JG003721-SI.pdfhttps://deepblue.lib.umich.edu/bitstream/2027.42/138300/3/jgrg20832.pd

Case report: First report on human infection by tick-borne Babesia bigemina in the Amazon region of Ecuador.

Babesiosis is a protozoan disease acquired by the bite of different species of ticks. More than 100 Babesia spp. infect wild and domestic animals worldwide, but only a few have been documented to infect humans. Generally, babesiosis is asymptomatic in immunocompetent persons; however, in immunocompromised can be life-threatening. A 13-year-old boy from the Amazon region presented with a 3-month evolution of fever, chills, general malaise, and arthralgia accompanied by anemia and jaundice. In the last 4 years was diagnosed with chronic kidney failure. By nested-PCR using 18S RNA ribosomal gene as target and DNA sequencing, the phylogenetic analysis showed Babesia bigemina as the causative agent in the blood. Treatment with oral quinine plus clindamycin for six continuous weeks was effective with no relapse occurring during 12 months of follow-up. This is the second human case in Ecuador but the first caused by the zoonotic B. bigemina which confirms the existence of active transmission that should alert public health decision-making authorities on the emergence of this zoonosis and the need for research to determine strategies to reduce tick exposure

GaSb-based solar cells for multi-junction integration on Si substrates

We report on the first single-junction GaSb solar cell epitaxially grown on a Si substrate. A control stand-alone GaSb solar cell was primarily fabricated, which demonstrated a 5.90% efficiency (AM1.5G). The preparation, growth and manufacturing procedures were then adapted to create the GaSb-on-Si solar cell. The hybrid device resulted in a degraded efficiency for which comparison between experimental and simulated data revealed dominant non-radiative recombination processes. Material and electrical characterization also highlighted the impact of anti-phase domains and boundaries and threading dislocation density on the shunt resistance of the cell. Nevertheless, the GaSb-on-Si cell performance is close to recent results on the integration of GaSb solar cells on GaAs, despite a much larger lattice mismatch (12% vs 8%). Routes for improvement, concerning the material quality and cell structure, are proposed. This work lays the foundations of a GaSb-based multi-junction solar cell monolithically integrated on Si

Height and timing of growth spurt during puberty in young people living with vertically acquired HIV in Europe and Thailand.

OBJECTIVE: The aim of this study was to describe growth during puberty in young people with vertically acquired HIV. DESIGN: Pooled data from 12 paediatric HIV cohorts in Europe and Thailand. METHODS: One thousand and ninety-four children initiating a nonnucleoside reverse transcriptase inhibitor or boosted protease inhibitor based regimen aged 1-10 years were included. Super Imposition by Translation And Rotation (SITAR) models described growth from age 8 years using three parameters (average height, timing and shape of the growth spurt), dependent on age and height-for-age z-score (HAZ) (WHO references) at antiretroviral therapy (ART) initiation. Multivariate regression explored characteristics associated with these three parameters. RESULTS: At ART initiation, median age and HAZ was 6.4 [interquartile range (IQR): 2.8, 9.0] years and -1.2 (IQR: -2.3 to -0.2), respectively. Median follow-up was 9.1 (IQR: 6.9, 11.4) years. In girls, older age and lower HAZ at ART initiation were independently associated with a growth spurt which occurred 0.41 (95% confidence interval 0.20-0.62) years later in children starting ART age 6 to 10 years compared with 1 to 2 years and 1.50 (1.21-1.78) years later in those starting with HAZ less than -3 compared with HAZ at least -1. Later growth spurts in girls resulted in continued height growth into later adolescence. In boys starting ART with HAZ less than -1, growth spurts were later in children starting ART in the oldest age group, but for HAZ at least -1, there was no association with age. Girls and boys who initiated ART with HAZ at least -1 maintained a similar height to the WHO reference mean. CONCLUSION: Stunting at ART initiation was associated with later growth spurts in girls. Children with HAZ at least -1 at ART initiation grew in height at the level expected in HIV negative children of a comparable age

Calendario de vacunaciones de la Asociación Española de Pediatría: recomendaciones 2019

El Comité Asesor de Vacunas de la Asociación Española de Pediatría publica anualmente el calendario de vacunaciones que estima idóneo para los niños residentes en España, teniendo en cuenta la evidencia disponible. En cuanto a las vacunas financiadas, se recomienda emplear el esquema 2 + 1 (2, 4 y 11 meses) con vacunas hexavalentes (DTPa-VPI-Hib-HB) y con antineumocócica conjugada 13-valente. Se aconseja un refuerzo a los 6 años, preferentemente con DTPa, junto con una dosis de polio para aquellos que recibieron esquemas 2 + 1, así como vacunación con Tdpa en adolescentes y en cada embarazo, entre la semana 27 y la 32. Se emplearán esquemas de 2 dosis para triple vírica (12 meses y 3-4 años) y varicela (15 meses y 3-4 años). La segunda dosis se podría aplicar como vacuna tetravírica. Se recomienda vacunación sistemática universal frente al VPH, tanto a chicas como a chicos, preferentemente a los 12 años, debiéndose realizar un mayor esfuerzo para mejorar las coberturas. La nueva vacuna de 9 genotipos amplía la cobertura para ambos sexos. Se recomienda que la vacuna antimeningocócica conjugada tetravalente (MenACWY) se introduzca en el calendario financiado a los 12 meses y a los 12-14 años, aconsejándose un rescate hasta los 19 años. Igualmente, se recomienda en los mayores de 6 semanas de edad con factores de riesgo o que viajen a países de elevada incidencia de estos serogrupos. Respecto a las vacunas no financiadas, se recomienda la antimeningocócica B, con esquema 2 + 1, solicitando su entrada en el calendario. Es recomendable vacunar a todos los lactantes frente al rotavirus. The Advisory Committee on Vaccines of the Spanish Association of Paediatrics annually publishes the immunisation schedule considered optimal for children resident in Spain, according to available evidence on current vaccines. As regards funded immunisations, the 2 + 1 strategy (2, 4, 11 months) with hexavalent (DTPa-IPV-Hib-HB) and 13-valent pneumococcal vaccines are recommended. Administration of the 6-year booster dose with DTPa is recommended, with a poliomyelitis dose for children who had received the 2 + 1 scheme, as well as Tdap vaccine for adolescents and pregnant women in every pregnancy between 27 and 32 weeks gestation. The 2-dose scheme should be used for MMR (12 months and 3-4 years) and varicella (15 months and 3-4 years). MMRV vaccine could be applied as the second dose. Vaccination against HPV is recommended in both genders, preferably at 12 years of age. A stronger effort should be made to improve vaccination coverage. The new 9-valent vaccine is now available, expanding the coverage for both genders. Tetravalent meningococcal vaccine (MenACWY) is recommended at 12 months and 12-14 years, with a catch-up up at 19 years of age. It is also recommended in infants older than 6 weeks of age with risk factors, or travellers to countries with high incidence of ACWY meningococcal serogroups. As regards non-funded immunisations, it is recommended meningococcal B vaccination, with a 2 + 1 schedule, and requests that it be included in the National Immunisation Program. Vaccination against rotavirus is recommended in all infants